Latvian
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)
migraine disorders/tūska
Saite tiek saglabāta starpliktuvē
Lappuse 1 no 16 rezultātiem
Method of treating migraine headache without aura
Rakstu tulkošanu var veikt tikai reģistrēti lietotāji
Ielogoties Reģistrēties
TECHNICAL FIELD OF THE INVENTION
The present invention relates to methods and compositions for treating selected conditions of the central and peripheral nervous systems employing non-synaptic mechanisms. More specifically, one aspect of the present invention relates to methods and compositions for
Prodrug salts
Rakstu tulkošanu var veikt tikai reģistrēti lietotāji
Ielogoties Reģistrēties
TECHNICAL FIELD
Provided are novel prodrug salts of selective aquaporin inhibitors, e.g., of aquaporin-4 and/or aquaporin-2, of Formula I as described below, their use as pharmaceuticals and pharmaceutical compositions comprising them, and novel intermediates used in and novel processes for their
Prodrug salts
Rakstu tulkošanu var veikt tikai reģistrēti lietotāji
Ielogoties Reģistrēties
TECHNICAL FIELD
Provided are novel prodrug salts of selective aquaporin inhibitors, e.g., of aquaporin-4 and/or aquaporin-2, of Formula I as described below, their use as pharmaceuticals and pharmaceutical compositions comprising them, and novel intermediates used in and novel processes for their
Methods and compositions for treating conditions of the central and peripheral nervous systems using non-synaptic mechanisms
Rakstu tulkošanu var veikt tikai reģistrēti lietotāji
Ielogoties Reģistrēties
TECHNICAL FIELD OF THE INVENTION
The present invention relates to methods and compositions for treating selected conditions of the central and peripheral nervous systems employing non-synaptic mechanisms. More specifically, one aspect of the present invention relates to methods and materials for
Method for pain relief using low power laser light
Rakstu tulkošanu var veikt tikai reģistrēti lietotāji
Ielogoties Reģistrēties
BACKGROUND OF THE INVENTION
Although it is often said that the common cold is the most prevalent disease among humankind, it is also true that chronic pain is an affliction that is almost as prevalent. Chronic headaches, muscle pain, joint pain, and the like are experienced by most individuals, and
Bumetanide analogs, compositions and methods of use
Rakstu tulkošanu var veikt tikai reģistrēti lietotāji
Ielogoties Reģistrēties
FIELD OF THE INVENTION
The present invention relates to bumetanide, furosemide, piretanide, azosemide, and torsemide analogs, including derivatives, positional isomers, and prodrugs thereof, compositions comprising the same and methods of making and using the same. The present invention also relates
N,N-substituted cyclic amine derivatives
Rakstu tulkošanu var veikt tikai reģistrēti lietotāji
Ielogoties Reģistrēties
INDUSTRIAL FIELD OF THE APPLICATION
The present invention relates to novel N,N-substituted cyclic amine compounds useful as a calcium antagonist, particularly as a nerve-selective calcium antagonist, specifically as an agent for treating and improving the diseases against which an inhibitory action
Substituted saturated aza heterocycles as inhibitors of nitric oxide synthase
Rakstu tulkošanu var veikt tikai reģistrēti lietotāji
Ielogoties Reģistrēties
CROSS REFERENCE TO RELATED APPLICATION
The present invention is based on, and claims priority from 60/008,390, filed Dec. 8, 1995.
BACKGROUND OF THE INVENTION
This application is directed to inhibitors of nitric oxide synthase, and in particular substituted azacycle derivatives.
Nitric Oxide in
Cyclic amidine analogs as inhibitors of nitric oxide synthase
Rakstu tulkošanu var veikt tikai reģistrēti lietotāji
Ielogoties Reģistrēties
BACKGROUND OF THE INVENTION
This application is directed to inhibitors of Nitric oxide synthase, and in particular cyclic amidines.
Nitric Oxide in Biology.
The emergence of nitric oxide (NO), a reactive, inorganic radical gas as a molecule contributing to important physiological and pathological
Aminoadamantane derivatives as therapeutic agents
Rakstu tulkošanu var veikt tikai reģistrēti lietotāji
Ielogoties Reģistrēties
BACKGROUND OF THE INVENTION
Certain adamantane derivatives have been used to treat illnesses. Rimantadine (1-(1-aminoethyl)adamantane) is used for the prophylaxis and treatment of influenza in humans. Amantadine has been used for the treatment of both influenza and Parkinson's disease (Schwab et
Aminoadamantane derivatives as therapeutic agents
Rakstu tulkošanu var veikt tikai reģistrēti lietotāji
Ielogoties Reģistrēties
BACKGROUND OF THE INVENTION
Certain adamantane derivatives have been used to treat illnesses. Rimantadine (1-(1-aminoethyl)adamantane) is used for the prophylaxis and treatment of influenza in humans. Amantadine has been used for the treatment of both influenza and Parkinson's disease (Schwab et
Aminoadamantane derivatives as therapeutic agents
Rakstu tulkošanu var veikt tikai reģistrēti lietotāji
Ielogoties Reģistrēties
BACKGROUND OF THE INVENTION
Certain adamantane derivatives have been used to treat illnesses. Rimantadine (1-(1-aminoethyl)adamantane) is used for the prophylaxis and treatment of influenza in humans. Amantadine has been used for the treatment of both influenza and Parkinson's disease (Schwab et
Aromatic and heteroaromatic substituted amides
Rakstu tulkošanu var veikt tikai reģistrēti lietotāji
Ielogoties Reģistrēties
FIELD OF INVENTION
The invention relates to a compound of formula ##STR1##
wherein R.sup.1 is selected from the group consisting of hydrogen and fluoro. Compounds of formula 1, and pharmaceutically acceptable acid addition salts thereof, have been shown to mediate the Neurokinin 1 (NK-1, substance
PTEN inhibitor or Maxi-K channels opener
Rakstu tulkošanu var veikt tikai reģistrēti lietotāji
Ielogoties Reģistrēties
TECHNICAL FIELD
The present invention relates to a new PTEN inhibitor or a new Maxi-K channels opener. More particularly, it relates to a PTEN inhibitor or new Maxi-K channels opener, which comprises as an active ingredient a tetrazolylalkoxy-dihydrocarbostyril compound of the formula
PTEN inhibitor or Maxi-K channels opener
Rakstu tulkošanu var veikt tikai reģistrēti lietotāji
Ielogoties Reģistrēties
TECHNICAL FIELD
The present invention relates to a new PTEN inhibitor or a new Maxi-K channels opener. More particularly, it relates to a PTEN inhibitor or new Maxi-K channels opener, which comprises as an active ingredient a tetrazolylalkoxy-dihydrocarbostyril compound of the formula
Vispilnīgākā ārstniecības augu datu bāze, kuru atbalsta zinātne
- Darbojas 55 valodās
- Zāļu ārstniecības līdzekļi, kurus atbalsta zinātne
- Garšaugu atpazīšana pēc attēla
- Interaktīva GPS karte - atzīmējiet garšaugus atrašanās vietā (drīzumā)
- Lasiet zinātniskās publikācijas, kas saistītas ar jūsu meklēšanu
- Meklēt ārstniecības augus pēc to iedarbības
- Organizējiet savas intereses un sekojiet līdzi jaunumiem, klīniskajiem izmēģinājumiem un patentiem
Ierakstiet simptomu vai slimību un izlasiet par garšaugiem, kas varētu palīdzēt, ierakstiet zāli un redziet slimības un simptomus, pret kuriem tā tiek lietota.
* Visa informācija ir balstīta uz publicētiem zinātniskiem pētījumiem
